8-K: Aclarion Inc. Files Audited Financials, Reveals Ongoing Concerns About Viability

Aclarion Inc. has released its audited financial statements for 2023 and 2022, highlighting recurring losses and substantial doubt about the company's ability to continue as a going concern.

Summary

• Aclarion Inc. filed its audited financial statements for the years ending December 31, 2023, and 2022.
• The company's financial statements for 2022 were restated to correct misstatements.
• The audit reports express substantial doubt about Aclarion's ability to continue as a going concern due to recurring losses and a deficiency in shareholders' equity.
• Aclarion reported a net loss of $4,911,374 in 2023, compared to a net loss of $7,068,593 in 2022.
• Revenue increased slightly from $60,444 in 2022 to $75,404 in 2023.
• Operating expenses decreased from $5,556,714 in 2022 to $4,875,657 in 2023.
• The company's cash and cash equivalents decreased from $1,472,806 in 2022 to $1,021,069 in 2023.
• Total assets decreased from $2,914,629 in 2022 to $2,459,774 in 2023.
• Total liabilities increased significantly from $688,671 in 2022 to $3,187,769 in 2023.
• The company has a negative stockholders' equity of $(727,995) in 2023, compared to a positive equity of $2,225,958 in 2022.
• Aclarion completed a 1-for-16 reverse stock split in January 2024.
• The company has entered into an equity line agreement with White Lion Capital, LLC, to potentially raise up to $10 million.

Sentiment

Score: 2

Explanation: The document reveals significant financial distress, with recurring losses, a negative equity position, and a going concern warning from auditors. While there are some minor improvements in revenue and operating expenses, the overall picture is very concerning for investors.

Positives

• The company's net loss decreased from $7,068,593 in 2022 to $4,911,374 in 2023.
• Revenue increased from $60,444 in 2022 to $75,404 in 2023.
• Operating expenses decreased from $5,556,714 in 2022 to $4,875,657 in 2023.
• The company has secured an equity line agreement with White Lion Capital, LLC, for potential funding of up to $10 million.

Negatives

• The company has recurring losses from operations and a deficiency in shareholders' equity.
• The auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Cash reserves decreased from $1,472,806 in 2022 to $1,021,069 in 2023.
• Total liabilities increased significantly from $688,671 in 2022 to $3,187,769 in 2023.
• The company's stockholders' equity went from $2,225,958 in 2022 to a deficit of $(727,995) in 2023.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and a deficiency in shareholders' equity.
• Aclarion needs to raise additional funds to continue its technology development and commercialization efforts.
• The company's cash reserves are limited, and it may need to raise additional capital to meet its obligations.
• The equity line agreement with White Lion Capital, LLC, may result in substantial dilution to existing shareholders.
• The company's financial statements for 2022 were restated to correct misstatements.

Future Outlook

The company believes it has sufficient cash to fund operations into the second quarter of 2024, but will need to raise additional funds to continue its technology development and commercialization efforts. Management has plans to secure such additional funding.

Management Comments

• Management's plans in regard to the company's going concern issues are described in Note 2 of the financial statements.
• Management believes that the cash on hand as of February 1, 2024, will fund operating expenses and capital expenditure requirements into the second quarter of 2024.

Industry Context

The healthcare technology sector is competitive, and Aclarion faces challenges in commercializing its technology and securing funding. The company's reliance on external funding and its current financial position are common issues for early-stage companies in this industry.

Comparison to Industry Standards

• Aclarion's revenue of $75,404 is very low compared to established medical technology companies, which often report revenues in the millions or billions of dollars.
• The company's net loss of $4,911,374 is significant for a company of its size and stage, and is not uncommon for early-stage biotech companies that are pre-revenue or in early commercialization.
• The negative stockholders' equity of $(727,995) is a major concern and indicates that the company's liabilities exceed its assets, which is not typical for companies with a stable financial position.
• The company's cash position of $1,021,069 is low and raises concerns about its ability to fund operations and growth, especially when compared to companies with more established revenue streams and access to capital.
• The company's reliance on equity financing and debt is common for early-stage companies, but the high level of debt and the need for additional funding raise concerns about its long-term viability.
• Compared to companies like Exact Sciences (EXAS) or Guardant Health (GH), which are also in the diagnostics space, Aclarion's financial metrics are significantly weaker, highlighting the challenges it faces in scaling its business.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from equity raises.
• Employees may be concerned about the company's long-term viability and job security.
• Customers may be concerned about the company's ability to continue providing its services.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional funding to continue its operations.
• The company may sell additional shares to White Lion Capital, LLC, under the equity line agreement.
• The company may negotiate additional exchanges of debt for common stock with accredited investors.
• The company needs to address the concerns raised by the auditors about its ability to continue as a going concern.

Key Dates

Keywords

financial statements, audited financials, going concern, net loss, revenue, operating expenses, reverse stock split, equity line, warrants, derivative liabilities